Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 5, 2022 7:00 AM EDT

Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners

XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, with a 30% Increase Over Q1 2021  

Preliminary Data from Phase 1/2 Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis to Be Presented at ASCO 2022

Promising Results from Pre-Specified Exploratory Subgroup Analysis in Patients with p53 Wild-Type Endometrial Cancer from the SIENDO Study; Planning Registration-Enabling Study Targeting Initiation in 2H 2022  

Recent Approvals Received by Partner... More